Épisodes maniaques et délirants aigus après traitement par sous idélalisib et ibrutinib. Première observation
S. De Almeida Chaves(Centre Hospitalier Universitaire de Toulouse), O. Beyne-rauzy, E. Dufranc(Centre Hospitalier Universitaire de Toulouse), D. Adoué, K. Delavigne(Human Technopole), P. Cougoul, Thibault Comont(Institut universitaire du cancer de Toulouse Oncopole), S. Ollier(Institut universitaire du cancer de Toulouse Oncopole), V. Nicolai(Institut universitaire du cancer de Toulouse Oncopole), Loïc Ysebaert(Institut universitaire du cancer de Toulouse Oncopole), S. Laclau(Hôpital Purpan)
Cited by 0
Related Papers
Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study
|The Lancet Infectious Diseases|2017|587
Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies
|Journal of Allergy and Clinical Immunology|2017|316
Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma
|Blood|2017|217
Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults
|Journal of Thrombosis and Haemostasis|2018|138